BUSINESS
Biocon Biologics, Civica ink deal to launch low-cost insulin glargine in US
Under the multi-year agreement, Biocon Biologics will manufacture and supply insulin glargine to Civica, which will commercialize the product under its own label.
BUSINESS
Graph AI secures $3 mn from Bessemer to automate drug safety monitoring
The company’s flagship product, Graph Safety, uses context-aware AI to automate the detection and reporting of adverse drug events (ADEs), a process traditionally handled by large teams of pharmacology graduates manually combing through call transcripts, legal filings, and medical literature.
BUSINESS
Single-specialty healthcare in India draws billions in investor capital, to become $31 billion by 2028
The single-specialty healthcare market, valued at Rs 126,000 crore ($15 billion) in 2024, is projected to surge to Rs 264,000 crore ($31 billion) by 2028, growing at a compound annual growth rate (CAGR) of 20 percent.
BUSINESS
Jupiter Life Line in Rs 1,400-crore expansion push in Maharashtra, to double capacity by 2029
As demand for quality specialist care grows in underserved urban clusters, the hospital chain plans increase the bed count from 1,061 to 2,500, CEO Ankit Thakker tells Moneycontrol
TRENDS
GSK calls for urgent focus on adult vaccination as ageing populations face rising disease burden
Data presented at the event showed that RSV is responsible for nearly 200,000 deaths and 2 million hospitalisations among adults aged over 60 in India alone over a five-year period.
BUSINESS
Everstone-backed Integris Medtech files for Rs 3,500-4,000 crore IPO
India’s second-largest coronary stent maker eyes debt reduction, global growth; FY25 adjusted profit jumps nearly 5x
BUSINESS
How tainted cough syrups slip through India’s broken drug oversight
India’s drug regulation system is split between the central and state governments, which often leads to confusion and weak enforcement.
BUSINESS
Indian patients demand transparency, willing to pay more for certified quality says FICCI & EY-Parthenon report
The findings, outlined in the ‘True Accountable Care’ report released (FICCI) and EY-Parthenon on Thursday, underscore a growing clamour for a national framework that establishes clear quality standards, moving the system beyond informal, word-of-mouth-based decisions.
BUSINESS
Roche faces setback as Delhi high court clears Natco Pharma's low cost generic Risdiplam
The court dismissed Roche’s plea for an injunction, citing public interest and the need for affordable access to the drug, which currently retails at over ₹600,000 per bottle under Roche’s brand name Evrysdi.
BUSINESS
Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’
The directive is similar to the one issued after India-made cough syrups were blamed for deaths of children in Gambia and Uzbekistan even as Coldrif toll climbs to 22 after two more children die
BUSINESS
Health adtech player Indegene rides Trump pharma shakeup with AI-driven outreach
'Whenever the pharma industry is under pressure, those are better times for us,' says CEO Manish Gupta
BUSINESS
Weight-loss drug Mounjaro is India's second-highest selling pharma brand
Mounjaro recorded sales of Rs 85 crore in September. Analysts say user-friendly pen formulation helped build the momentum, expected to get a further boost from GST cuts
BUSINESS
USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.
BUSINESS
Centre proposes Rs 5,000 crore R&D booster for Pharma and MedTech: Can it drive innovation?
The initiative, backed by a total financial outlay of Rs 5,000 Crore (nearly $600 million) spanning from FY 2023-24 to FY 2029-30, is designed to shift the life sciences economy from a volume-driven, cost-based generic manufacturing hub to an innovation-centric global competitor.
BUSINESS
Wockhardt applies to seek USFDA nod for ‘miracle’ antibiotic Zaynich
The Mumbai-based company is eyeing a US launch in FY27, marking a pivotal moment for Indian pharma innovation.
BUSINESS
Aditya Birla Education Trust expands mental health & education outreach, touches 3.8 million lives
The push comes as nearly 150 million Indians grapple with stress, anxiety, and depression, yet less than 25% seek help, according to ABET’s latest impact report.
BUSINESS
Indegene acquires BioPharm to boost AI-powered pharma marketing
The deal, executed through Indegene’s US subsidiary ILSL Inc., aims to strengthen the company’s omnichannel and media offerings by integrating BioPharm’s precision marketing expertise with Indegene’s data and analytics platforms.
BUSINESS
Generic drug approvals in US poised for a rise, Indian drugmakers continue to dominate
USFDA approvals are vital for India, which exported $10 billion worth of generic medicines to US in FY25
BUSINESS
Somerset Indus Capital Partners exits Apex Hospitals with 4x return
Somerset’s investment in Apex began in May 2019, during which the hospital group tripled its revenue and doubled its workforce, expanding access to quality healthcare across Tier 2 and Tier 3 cities in Rajasthan.
BUSINESS
Fertility services firm Gaudium IVF re-files IPO with Sebi with a higher OFS portion
The offer now comprises a fresh issue of up to 1.13 crore equity shares and an offer for sale (OFS) of up to 94.94 lakh shares by Dr. Khanna.
BUSINESS
Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.
BUSINESS
Lupin to acquire VISUfarma for euro 190 million, expanding European specialty footprint
In 2024, VISUfarma, backed by GHO Capital, reported a revenue of 48.1 million. It operates in all major European markets, including Italy, the UK, Spain, Germany, and France
BUSINESS
Sun Pharma may face tariff turbulence in US but HSBC sees limited earnings risk
HSBC outlines several mitigation strategies for Sun Pharma, including shifting manufacturing to CDMO partners with US-based plants.
BUSINESS
Trump’s 100% drug tariff: A mixed bag for India’s CRDMO industry
“Few Indian pharma companies with exposure to non-U.S. domiciled branded formulation or innovator drug companies, who in turn export to the U.S., may face challenges,” said Deepak Jotwani, VP & Sector Head, ICRA.
